<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0"><channel><title>medsurfnews.com</title><link>http://www.medsurfnews.com</link><description>Last resources from Medsurfnews.com</description><language>it</language><pubDate></pubDate><copyright>Healthware.it</copyright><webmaster>francesco.raimondo@healthware.it</webmaster><image><title>Medsurfnews Rss</title><url>http://www.medsurfnews.com/images/logo.jpg</url><link>http://www.medsurfnews.com</link></image>
	
	
	
<item>
<category>Orthopaedics</category>
<title>Evaluation of Osteoporotic Fracture Risk</title>
<link>http://www.medsurfnews.com/contents/en/7308/display/evaluation-of-osteoporotic-fracture-risk.aspx</link>
<description><![CDATA[The diagnosis of osteoporosis and its consequent pharmacological treatment are based on T-score assessment, obtained through DEXA. In recent times, prediction models of fracture risk at 10 years have been created and researchers have tried to see how these predictions can influence the use of pharmacological therapy.]]></description>
<pubDate>Mon, 21 May 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Bisphosphonates and Risk of Hip Fractures</title>
<link>http://www.medsurfnews.com/contents/en/7259/display/bisphosphonates-and-risk-of-hip-fractures.aspx</link>
<description><![CDATA[For the treatment of postmenopausal and of cortisone-related osteoporosis, the primary role is kept by bisphosphonates, even if some studies have suggested a possible link between the continued use of these molecules and the onset of low-energy hip fractures (subtrochanteric or diaphisary ones), a consequence of an interference with bone reabsorption.]]></description>
<pubDate>Mon, 7 May 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Acute multidisciplinary treatment strategy for patients with a hip fracture</title>
<link>http://www.medsurfnews.com/contents/en/7228/display/acute-multidisciplinary-treatment-strategy-for-patients-with-a-hip-fracture.aspx</link>
<description><![CDATA[Implementation of the interventions requires continued focus on supervision and training of staff to complete fulfilment. Experience shows that the checklist is not always filled, but that data can be found in the patient record. It is too early to comment on whether patient mortality is reduced.  There are the conclusions of a intervention study with retrospective control group.]]></description>
<pubDate>Tue, 17 Apr 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Breakeven, Cost Benefit, Cost Effectiveness, and Willingness to Pay for Web-Based Versus Face-to-Face Education Delivery for Health Professionals</title>
<link>http://www.medsurfnews.com/contents/en/7180/display/breakeven-cost-benefit-cost-effectiveness-and-willingness-to-pay-for-web-based-versus-face-to-face-education-delivery-for-health-professionals.aspx</link>
<description><![CDATA[The introduction of Web-based education and open universities has seen an increase in access to professional development within the health professional education marketplace. A study compares costs and effects of Web-based and face-to-face short courses in falls prevention education for health professionals. Results showed that Web-based educational approach was clearly more efficient from the perspective of the education provider. ]]></description>
<pubDate>Tue, 3 Apr 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Glitazones and Fractures</title>
<link>http://www.medsurfnews.com/contents/en/7160/display/glitazones-and-fractures.aspx</link>
<description><![CDATA[Both in randomized and observational studies, glitazones (pioglitazone and rosiglitazone) have been associated with an increased risk of fracture and the biological explanation is convincing: activating PPAR-gamma bone receptors (a wide group of proteins intervening in transcription processes) interferes with bone metabolism.]]></description>
<pubDate>Mon, 26 Mar 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Plasma proteins take their toll on the joint in osteoarthritis</title>
<link>http://www.medsurfnews.com/contents/en/7125/display/plasma-proteins-take-their-toll-on-the-joint-in-osteoarthritis.aspx</link>
<description><![CDATA[Results of a recent study may demonstrate a novel mechanism by which synovial inflammation can be initiated in patients with OA and how this process may contribute to the pathogenesis of OA joint pathology.
]]></description>
<pubDate>Tue, 13 Mar 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>No Advantage for New Hip Implants Over Traditional Ones</title>
<link>http://www.medsurfnews.com/contents/en/6920/display/no-advantage-for-new-hip-implants-over-traditional-ones.aspx</link>
<description><![CDATA[New types of hip implants, using metal-on-metal or ceramic-on-ceramic bearings, appear to have no significant advantage over traditional implants, according to a systematic review of clinical trials, observational studies, and national registries published online November 29 in the British Medical Journal.
]]></description>
<pubDate>Tue, 6 Dec 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Menopausal Osteoporosis</title>
<link>http://www.medsurfnews.com/contents/en/6845/display/menopausal-osteoporosis.aspx</link>
<description><![CDATA[Despite there is not drugs capable to reduce the risk of fractures of 50%-70% after 6-12 months of treatment, postmenopausal osteoporosis often remains not recognized and consequently not treated, with easily foreseeable consequences. The North American Menopause Society (NAMS), in its declarations in 2010, affirms that all women in post-menopause should be assessed for risk factors associated with osteoporosis, to recognize fracture risk factors, to eliminate possible causes for secondary osteoporosis, to modify risk factors and to choose candidates for pharmacological therapy.]]></description>
<pubDate>Mon, 7 Nov 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Thrombotic Prophylaxis in Orthopedic Surgery</title>
<link>http://www.medsurfnews.com/contents/en/6826/display/thrombotic-prophylaxis-in-orthopedic-surgery.aspx</link>
<description><![CDATA[In patients undergoing orthopedic surgery, a long-acting anti-thrombotic prophylaxis is usually performed, but is this practice really useful and necessary? Through a multinational trial, sponsored by pharmaceutical industry, the efficacy of a long-term prophylaxis in acute patients has been assessed: everybody has been treated with enoxaparin for 10 days, then all have been randomized to receive further injections of heparin or placebo for 28 further days. Controls have been made when 75% of enrolment was reached (3685 patients) and there have been no differences between enoxaparin and placebo as to thromboembolic events; there has been, instead, a greater tendency to bleeding episodes in the group treated with heparin (0.6% vs. 0.29%).]]></description>
<pubDate>Mon, 31 Oct 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Orthopaedics</category>
<title>Risk Factors for Complications after Spine Surgery</title>
<link>http://www.medsurfnews.com/contents/en/6717/display/risk-factors-for-complications-after-spine-surgery.aspx</link>
<description><![CDATA[The study authors evaluated the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database for the years 2005 to 2008. This database documents preoperative information and postoperative complications and death among patients receiving surgery at participating medical facilities across the United States. 
]]></description>
<pubDate>Tue, 20 Sep 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	</channel></rss>
	



